The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders
(2012) Medical Clinics of North America — Vol. 96, n° 3, p. 583-619 (2012)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- In this article, the evidence on the clinical use of monoclonal antibodies in the treatment of immune-mediated hematologic disorders is described. Insights into pathogenic mechanisms have revealed a major role of both B and T cells. Controlled trials have shown conflicting results, necessitating further research regarding pathogenesis, mechanism of action, and resistance. Although the use of more potent and specific monoclonal antibody therapy, mainly targeting costimulation signals, may improve response rates and long-term outcome, its use should be carefully balanced against potential side effects. © 2012 Elsevier Inc.
- Affiliations
Citations
Dierickx, D., Beke, E., Devos, T., & Delannoy, A. (2012). The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America, 96(3), 583-619. https://doi.org/10.1016/j.mcna.2012.04.006 (Original work published 2012)